Everyone said brain disorders were too tough to tackle... we said they are too important not to.
At Sage, we:
- think differently about brain disorders and how we approach the discovery and development of new medicines.
- search for solutions that have the potential to work faster and last longer, to radically—not just incrementally—improve the lives of patients and their families.
- leverage our distinct approach to translational medicines and science to drive efficiency in our drug development approach.
We are pursuing new pathways with the goal of improving brain health. Our depression, neurology and neuropsychiatry programs aim to change how brain disorders are thought about and treated. Although brain disorders are our primary focus, we may also evaluate opportunities in adjacent areas of interest. We are committed to growing our portfolio, starting with a robust R&D process evaluating the safety and efficacy of our novel drug candidates with the goal of potentially addressing gaps in available treatment options for debilitating diseases. To rapidly advance our clinical development programs, we design efficient studies to look for profound therapeutic effects, and partnered opportunities will be developed using the same principles.
Partnership Focus at Sage
With our distinct approach to discovering and developing new medicines, we have built a pipeline of differentiated assets.
We are interested in exploring strategic partnerships that:
- Complement our GABA platform
- We’ve built tremendous capabilities around the GABA research area but believe more is out there.
- Expand on our NMDA platform
- We see great promise in the NMDA research area and are opportunistic in ways to augment the innovative work we have already done
- Introduce novel mechanisms of action
- Our team is driven to create first-in-class or best-in-class medicines with the potential to get patients better, sooner.
Our commitment to growing our portfolio includes evaluating opportunities that meet the following criteria:
- Asset stage: preclinical through commercial
- Modality: small molecules are preferred, but we are opportunistic on biologics with compelling data
- Indications: most brain disorders representing clear unmet medical needs